ClinicalTrials.gg
Status unknownNCT04856670Updated May 12, 2021

Assessing Diabetes Mellitus on Cytokine Analysis and Macular Edema Following FLACS

An observational study in Cystoid Macular Edema, Diabetes Mellitus and Cataract, sponsored by Uptown Eye Specialists. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-12.

Sponsored by Uptown Eye Specialists · Observational

How we know

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
140
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies in Macular Edema with a site in Canada — none open to participants now, 2 under way, none of them phase 3. Macular Edema · Canada.

Started
2021
with 3 others
Observational
3 of 53
none open now
Registered
48th of 53
by date

Among the 53 studies in Macular Edema with a site in Canada, this one is one of 4 that started in 2021, is one of 3 observational ones, and was the 48th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 53 studies in Macular Edema with a site in Canada is open now. The open studies under Macular Edema, anywhere →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 53 studies in Macular Edema with a site in Canada as a file.
02

Study summary

The purpose of this study is to assess the effects of diabetes mellitus (DM) on anterior chamber cytokine production and postoperative macular edema in patients undergoing femtosecond laser-assisted cataract surgery (FLACS). Patients with DM routinely undergo FLACS, yet the majority of studies evaluating intraocular inflammation following femtosecond laser treatment have excluded this patient population. Importantly, DM alters the inflammatory status of the eye, which may influence the production of inflammatory mediators following femtosecond laser treatment and the development of postoperative macular edema. The results from this study will provide insight into the risks and benefits of FLACS in patients with DM.

Read the detailed description

As discussed above.

03

Conditions studied

  • Cystoid Macular Edema
  • Diabetes Mellitus
  • Cataract
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients enrolling for Cataract surgery at Uptown Eye Specialists

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients who are scheduled for manual cataract surgery or FLACS who have provided , in accordance with application regulations and guidelines.
  • Only one eye from each participant will be included in the study (the first one to be operated on).

Exclusion criteria

Exclusion Criteria:

  • Intravitreal anti-VEGF injection \< 3 months prior to cataract surgery
  • Laser photocoagulation \< 3 months prior to cataract surgery
  • Complications during manual cataract surgery or FLACS
  • Current or previous ocular or systemic inflammation
  • History of rheumatic or immune disease
  • Poor pharmacologic mydriasis
  • Corneal opacities
  • Pseudoexfoliation syndrome
  • Previous ocular surgery or trauma
  • Use of topical or systemic \< 6 months prior to surgery
  • Prostaglandin analog eyedrop therapy
  • Glaucoma
  • Age-related macular degeneration
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
140 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control patients undergoing manual cataract surgery

    As above

    Procedure: Cataract surgery

  • Control patients undergoing FLACS

    Femtosecond laser assisted cataract surgery

    Procedure: Cataract surgery

  • Diabetic patients undergoing manual cataract surgery

    As Above

    Procedure: Cataract surgery

  • diabetic patients undergoing FLACS

    As Above

    Procedure: Cataract surgery

Interventions

  • ProcedureCataract surgery

    Cataract surgery- Manual or femtosecond laser assisted

06

What researchers measure

Primary outcomes

  1. Aqueous humor concentrations of inflammatory mediators at the onset of manual cataract surgery and following femtosecond laser treatment

    Cytokine concentration at time of cataract surgery

    Time frame: 1 day

Secondary outcomes

  1. Prevalence of postoperative macular edema in control and diabetic participants

    Macular edema post operatively

    Time frame: Post op day 1, week 1, month 1 and month 3

  2. Postoperative change in central retinal thickness

    Central retinal thickness postoperatively

    Time frame: Post op day 1, week 1, month 1 and month 3

  3. Postoperative change in macular volume

    macular volume postoperatively

    Time frame: Post op day 1, week 1, month 1 and month 3

  4. Microvascular changes and development of cystic macular lesions

    Slit lamp exam of microvascular changes and development of cystic macular lesions

    Time frame: Post op day 1, week 1, month 1 and month 3

  5. Best corrected visual acuity

    Change in visual acuity overtime

    Time frame: Post op day 1, week 1, month 1 and month 3

  6. Prevalence and severity of postoperative flare

    Slit lamp exam for prevalence and severity of postoperative flare

    Time frame: Post op day 1, week 1, month 1 and month 3

07

Study locations

1 site
  • Uptown Eye Speicialists
    Brampton, Otario L6Y0P6, Canada
08

References and documents

Publications

  • Wu H, Hwang DK, Song X, Tao Y. Association between Aqueous Cytokines and Diabetic Retinopathy Stage. J Ophthalmol. 2017;2017:9402198. doi: 10.1155/2017/9402198. Epub 2017 Jun 7. PubMed 28680705 ↗
  • Dong N, Xu B, Wang B, Chu L, Tang X. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery. Biomed Res Int. 2015;2015:126984. doi: 10.1155/2015/126984. Epub 2015 Feb 25. PubMed 25811020 ↗
  • Agarwal A, Jacob S. Current and effective advantages of femto phacoemulsification. Curr Opin Ophthalmol. 2017 Jan;28(1):49-57. doi: 10.1097/ICU.0000000000000333. PubMed 27801688 ↗
  • Favuzza E, Becatti M, Gori AM, Mencucci R. Cytokines, chemokines, and flare in the anterior chamber after femtosecond laser-assisted cataract surgery. J Cataract Refract Surg. 2019 Jul;45(7):910-914. doi: 10.1016/j.jcrs.2019.01.040. PubMed 31262481 ↗
  • Liu YC, Setiawan M, Ang M, Yam GHF, Mehta JS. Changes in aqueous oxidative stress, prostaglandins, and cytokines: Comparisons of low-energy femtosecond laser-assisted cataract surgery versus conventional phacoemulsification. J Cataract Refract Surg. 2019 Feb;45(2):196-203. doi: 10.1016/j.jcrs.2018.09.022. Epub 2018 Dec 6. PubMed 30528516 ↗
  • Wang L, Zhang Z, Koch DD, Jia Y, Cao W, Zhang S. Anterior chamber interleukin 1beta, interleukin 6 and prostaglandin E2 in patients undergoing femtosecond laser-assisted cataract surgery. Br J Ophthalmol. 2016 Apr;100(4):579-82. doi: 10.1136/bjophthalmol-2015-307586. Epub 2015 Dec 11. PubMed 26659713 ↗
  • Chen H, Lin H, Zheng D, Liu Y, Chen W, Liu Y. Expression of Cytokines, Chmokines and Growth Factors in Patients Undergoing Cataract Surgery with Femtosecond Laser Pretreatment. PLoS One. 2015 Sep 2;10(9):e0137227. doi: 10.1371/journal.pone.0137227. eCollection 2015. PubMed 26331724 ↗
  • Chen H, Zhang X, Liao N, Wen F. Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy. BMC Ophthalmol. 2017 Oct 2;17(1):176. doi: 10.1186/s12886-017-0572-6. PubMed 28969616 ↗
  • Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC; United Kingdom Pseudophakic Macular Edema Study Group. Risk Factors and Incidence of Macular Edema after Cataract Surgery: A Database Study of 81984 Eyes. Ophthalmology. 2016 Feb;123(2):316-323. doi: 10.1016/j.ophtha.2015.10.001. Epub 2015 Dec 8. PubMed 26681390 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2021; primary completion for Sep 2021, 3 months later.

Of 44 observational studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2020
First posted
Apr 23, 2021
StartEst.
May 25, 2021
Primary completionEst.
Sep 15, 2021
CompletionEst.
Sep 15, 2021
Last update
May 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04856670
Lead sponsor
Uptown Eye Specialists
Responsible party
Sponsor
First posted
Apr 23, 2021
Start date
May 25, 2021 (estimated)
Primary completion
Sep 15, 2021 (estimated)
Completion
Sep 15, 2021 (estimated)
Last update
May 12, 2021

Study contacts

Sohel Somani, MD, FRCSC
Contact
sydney@emdi.ca
416.292.0330
sydney@emdi.ca Somani, MD, FRCSC
principal investigator · Uptown Eye Specialists

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion